Therapeutics for Women's Health: Technologies and Global Markets

The global market for women’s health therapeutics was worth nearly $18.3 billion in 2012. The market is expected to increase from nearly $19 billion in 2013 to nearly $22.5 billion by 2018, a compound annual growth rate (CAGR) of 3.5% for the five-year period, 2013 to 2018.

Report Includes

• An overview of the global therapeutics for women's health market.
• Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
• Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
• Detailed analysis of annual costs as well discussion on branded vs. generics.
• Specifics on market factors such as drivers, restraints, competition, and market shares.
• Information on marketed as well as pipeline drugs and therapies.

• The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
• The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
• Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%.

• The total U.S. market for new therapeutics and diagnostics for women’s disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an AAGR (average annual growth rate) of 10.3%.
• Treatments for cancers specific to women will rise the fastest, at an AAGR of 12.6% and will lead revenues in 2009.
• Reproductive-related therapies and diagnostics currently represent the largest market segment, but, rising at an AGR of 8.4%, will lag slightly by 2009.
• Treatments for gynecological diseases and infections and for rheumatoid arthritis and osteoporosis also represent large market segments.

• The total current U.S. market for new therapeutics and diagnostics for women's disorders in 1999 reached $16.9 billion at the manufacturers' level. The growing numbers of women combined with the growing trend to take an active role in healthcare has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $31.9 billion, growing at an average annual rate of 8.7%.
• The reproductive-related therapeutics and diagnostics holds the largest market revenues position representing 31.9% and accounting for $5.4 billion of the total in 1999. Large numbers of women in the baby boomer age group, coupled with large numbers of the mini-boomers (daughters of the baby boomer generation), contributed to the reproductive-related therapeutics and diagnostics' dominate role in 1999. It is anticipated that the reproductive-related therapeutics and diagnostics will remain the largest market share throughout the forecast period as it crosses $10 billion by 2005.